Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | EBP | Q15125 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10900908 | 0.91 | SIGMAR1 (0.67) | KCNH2KCNJ1SIGMAR1HRH1HDAC4 | |
| SCHEMBL5857485 | 0.87 | KCNH2 (0.57) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL7772142 | 0.85 | SLC6A3 (0.61) | KCNH2SIGMAR1EBPSLC6A3DHCR7 | |
| SCHEMBL10899595 | 0.84 | KCNH2 (0.57) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL10900445 | 0.84 | KCNH2 (0.57) | KCNH2KCNJ1SIGMAR1SLC6A4SLC6A2 | |
| SCHEMBL7031548 | 0.83 | HRH3 (0.62) | KCNH2SIGMAR1EBPSLC6A3DHCR7 | |
| SCHEMBL2741683 | 0.83 | HRH3 (0.62) | KCNH2SIGMAR1EBPSLC6A3DHCR7 | |
| Hydrochloric Acid SCHEMBL7447525 | 0.83 | SLC6A3 (0.59) | KCNH2SIGMAR1EBPSLC6A3DHCR7 | |
| SCHEMBL1160126 | 0.83 | SIGMAR1 (0.62) | KCNH2SIGMAR1MEN1KMT2AHRH3 | |
| SCHEMBL10902405 | 0.83 | MEN1 (0.67) | KCNH2SIGMAR1EBPSLC6A3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102203280-A | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS INC | 2011-09-28 | — | — | CN | disclosed |
| CN-102056890-A | Polymerizable type II photoinitiators and curable compositions | AGFA GRAPHICS NV | 2011-05-11 | — | — | CN | disclosed |
| US-7125906-B2 | Indole derivatives having anti-angiogenetic activity | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-7030123-B2 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | US | disclosed |
| EP-1515716-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | Astrazeneca AB (SE) | 2005-03-23 | — | — | EP | disclosed |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
| WO-2003082271-A2 | INDOLE DERIVATIVES HAVING ANTI-ANGIOGENETIC ACTIVITY | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
| EP-1289952-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | AstraZeneca AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092224-A1 | INDOLE DERIVATIVES WITH VASCULAR DAMAGING ACTIVITY | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
| US-4616086-A | ANTICOAGULANTS | BOEHRINGER MANNHEIM GMBH (DE) | 1986-10-07 | — | — | US | disclosed |
| EP-0076996-A1 | Carboxylic-acid derivatives, process for their preparation and medicines containing them | Roche Diagnostics GmbH (DE) | 1983-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159474-A1 | Angiogenesis inhibitors for cardiovascular disorders, neovascularization | FLT1, FLT4, VEGFA | KCNH2 2673/4885KCNJ1 2623/4885SIGMAR1 2389/4885 |
| US-20030216356-A1 | Indole derivatives with vascular damaging activity | IDO1, IDO2, VEGFA | KCNH2 939/4885KCNJ1 2400/4885SIGMAR1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.